<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198495</url>
  </required_header>
  <id_info>
    <org_study_id>COPEFER</org_study_id>
    <nct_id>NCT02198495</nct_id>
  </id_info>
  <brief_title>Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients</brief_title>
  <acronym>COPEFER</acronym>
  <official_title>Continuous Versus Periodic Intravenous Iron Supplementation in Maintenance Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with end-stage kidney disease on maintenance hemodialysis frequently require iron
      supplementation to compensate for ongoing iron losses, and to maintain hemoglobin levels with
      or without additional use of erythropoiesis-stimulating agents (ESA).

      The investigators aim to compare two different intravenous iron preparations, ferric
      carboxymaltose and iron sucrose in 140 hemodialysis patients. The investigators primary
      objective is to assess whether both agents are equally effective to maintain a target
      haemoglobin within 10-12 mg/dl. The investigators will also measure ferritin, transferrin,
      transferrin saturation, and how much ESA therapy is administered.

      Patients will be randomly assigned to either treatment group and followed in parallel over an
      active study period of 40 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum hemoglobin level (g/dl)</measure>
    <time_frame>40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin level (µg/l)</measure>
    <time_frame>Week 0, 10, 20, 30, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum transferrin level (mg/dl)</measure>
    <time_frame>Week 0, 10, 20, 30, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of transferrin saturation (TSAT) (%)</measure>
    <time_frame>Week 0, 10, 20, 30, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESA consumption in I.E./week or µg/week as appropriate</measure>
    <time_frame>Week 0, 10, 20, 30, 40</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplementation of ferric carboxymaltose</intervention_name>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplementation of iron sucrose</intervention_name>
    <arm_group_label>Iron sucrose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Male and female patients aged ≥ 18

          -  Patients with anemia and end stage kidney disease on dialysis

          -  Hemoglobin ≥ 8,5g/dl

          -  Ferritin &lt; 1000mg/dl

          -  TSAT &lt; 50%

          -  CRP &lt; 5mg/dl

        Exclusion Criteria:

          -  Hemoglobin &lt; 8,5g/dl

          -  Pregnancy or Nursing

          -  Known allergic reaction to i.v. iron supplementation or to ingredients of
             Investigational Medicinal Product (IMP)

          -  Chronic infections (HIV, Hep B, Hep C)

          -  Acute infections (CRP&gt;5mg/dl; Antibiotic therapy except for prophylactic use)

          -  Malignant tumor disease

          -  Oral iron supplementation at study inclusion

          -  Participation in a different study at the same time

          -  Active bleeding issues

          -  Surgical intervention within the last 4 weeks before study inclusion

          -  Mental diseases

          -  Bronchial asthma

          -  Atopic allergy

          -  Eczema

          -  Receipt of red blood cell (RBC) concentrate within the last 4 weeks before study
             inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gere Sunder-Plassmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernhard O Bielesz, MD</last_name>
    <phone>0043 1 40400</phone>
    <phone_ext>43900</phone_ext>
    <email>bernhard.bielesz@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna, Division of Nephrology and Dialysis</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard O Bielesz, MD</last_name>
      <phone>0043 1 40400</phone>
      <phone_ext>43900</phone_ext>
      <email>bernhard.bielesz@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Bernhard O Bielesz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wiener Dialysezentrum GmbH</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Lorenz, MD</last_name>
      <phone>0043 1 908</phone>
      <phone_ext>1310</phone_ext>
      <email>matthias.lorenz@dialysewien.at</email>
    </contact>
    <investigator>
      <last_name>Matthias Lorenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>September 17, 2016</last_update_submitted>
  <last_update_submitted_qc>September 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gere Sunder-Plassmann</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

